GlassScriptPhysician profile
Sean B Wilen
NPI 1225568652
$4,799.84
in general payments reported to CMS, 2019-2025
49 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $647 · 2023: $937 · 2024: $857 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,051.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $797.20 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $355.52 | 2022-2025 | Synthroid, Vraylar |
| Boston Scientific Corporation | $290.49 | 2022-2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $284.84 | 2022-2025 | |
| Janssen Biotech, INC. | $262.75 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $254.49 | 2022-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $242.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $219.33 | 2021-2025 | Korlym |
| Glaxosmithkline, LLC. | $213.40 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $182.22 | 2023-2025 | Symplicity G3, Minimed 780g |
| Xeris Pharmaceuticals, INC. | $162.23 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $126.43 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $123.63 | 2022-2025 | Belsomra, Capvaxive, Verquvo |
| Exact Sciences Corporation | $116.00 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $111.37 | 2021-2025 | Entyvio, Eohilia |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $91.28 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Kowa Pharmaceuticals America, INC. | $72.10 | 2024-2025 | Zoryve |
| Abbott Laboratories | $67.26 | 2022-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $67.07 | 2023-2024 | Ibsrela |
| Harmony Biosciences LLC | $52.97 | 2023-2024 | Wakix |
| Phathom Pharmaceuticals, INC. | $51.66 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $48.77 | 2024 | Veozah |
| Pfizer INC. | $47.66 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $45.86 | 2024 | |
| Alexion Pharmaceuticals, INC. | $44.94 | 2022-2023 | Strensiq |
| Dexcom, INC. | $41.05 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $34.61 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $33.35 | 2025 | |
| Braintree Laboratories, INC. | $32.67 | 2023-2024 | Suflave, Sutab |
| Mallinckrodt Hospital Products INC. | $18.94 | 2025 | Acthar |
| Aimmune Therapeutics, INC. | $18.56 | 2025 | Zenpep |
| Djo, LLC | $17.90 | 2025 | Cmf |
| Bausch Health US, LLC | $17.86 | 2023 | Aplenzin |
| Axsome Therapeutics, INC. | $17.77 | 2025 | Sunosi |
| Antares Pharma, INC. | $17.56 | 2023 | Xyosted, Nocdurna, Tlando |
| Insulet Corporation | $17.49 | 2023 | Omnipod |
| Esperion Therapeutics, INC. | $17.41 | 2022 | |
| Sumitomo Pharma America, INC. | $17.21 | 2025 | Gemtesa |
| Mayne Pharma Commercial LLC | $17.00 | 2023 | |
| Resmed Corp | $16.72 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.29 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $16.08 | 2023 | Horizant |
| Lundbeck LLC | $15.54 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $14.93 | 2025 | Fanapt |
| Tolmar, INC. | $14.65 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $14.29 | 2021 | |
| Bavarian Nordic A/S | $13.84 | 2025 | Vivotif |
| Amneal Pharmaceuticals LLC | $13.63 | 2021 | |
| Hydrocision, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Wilen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.